J Med Microbiol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ivanov, I. B.
Right arrow Articles by Kuzmin, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ivanov, I. B.
Right arrow Articles by Kuzmin, M. D.
Agricola
Right arrow Articles by Ivanov, I. B.
Right arrow Articles by Kuzmin, M. D.
J Med Microbiol 55 (2006), 1645-1648; DOI: 10.1099/jmm.0.46752-0
© 2006 Society for General Microbiology
ISSN 1473-5644

Staphylococcal secretory inhibitor of platelet microbicidal protein is associated with prostatitis source

Iuri B. Ivanov, Viktor A. Gritsenko and Michael D. Kuzmin

Department of Human Microbiology, Institute of Cellular and Intracellular Symbiosis, Russian Academy of Sciences, Orenburg, Russia

Correspondence
Iuri B. Ivanov
mil-for{at}rambler.ru

Received 1 June 2006
Accepted 16 August 2006

This study reports the detection of an extracellular staphylococcal product, designated secretory inhibitor of platelet microbicidal protein (SIPMP), that causes local inhibition of the bactericidal action of platelet microbicidal protein (PMP) in the fluid phase. Urethral isolates of Staphylococcus aureus (n=24) and coagulase-negative staphylococci (CNS) (n=47) from patients with or without chronic bacterial prostatitis (CBP) were tested. SIPMP production was tested by inhibition of PMP bioactivity against Bacillus subtilis and was expressed as percentage inhibition of PMP bactericidal activity. The PMP susceptibility of staphylococcal strains was determined by exposing bacterial cells to serial dilutions of PMP. Staphylococci from patients without CBP produced SIPMP at levels of 10.3±1.2 and 13.25±1.72 % for S. aureus and CNS, respectively. Strains isolated from men with CBP inhibited PMP-induced killing of B. subtilis by 23.38±4.2 % (P<0.05) and 23.69±1.87 % (P<0.01) for S. aureus and CNS, respectively. SIPMP production correlated with staphylococcal resistance to PMP (r2=0.6082 and 0.7264 for S. aureus and CNS, respectively). SIPMP represents a hitherto unrecognized determinant of staphylococcal pathogenicity. These results suggest that SIPMP production is associated with the CBP source. Data from this study may have significant implications for the understanding of the pathogenesis of CBP.

Abbreviations: CBP, chronic bacterial prostatitis; CNS, coagulase-negative staphylococci; PMP, platelet microbicidal protein; SIPMP, secretory inhibitor of platelet microbicidal protein.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2006 Society for General Microbiology.